BACKGROUND: Silent coronary artery disease is a frequent complication of type 2 diabetes (T2DM). Based on its multiple roles in inflammation, atherogenesis and glucose homeostasis, we hypothesised that activin A could be related to coronary atherosclerosis in T2DM. METHODS: Activin A and follistatin were measured in 102 patients with T2DM and 20 age- and sex-matched healthy controls. Coronary angiography was performed in a sub-population of patients and associations with activin A were examined using multiple linear regression. RESULTS: Serum activin A and the activin A/follistatin ratio were increased in patients with T2DM and coronary artery disease (CAD) compared with healthy volunteers and the elevated activin A was associated with the severity of coronary atherosclerotic burden as determined by the proportion of ≥2 vessel disease (p = 0.035) after multivariable-adjusted trend analysis. No significant association between presence of CAD or extent score and activin A was observed. CONCLUSION: In patients with T2DM, increased activin A may reflect chronic underlying pathophysiological processes involved in development of cardiovascular disease.
BACKGROUND: Silent coronary artery disease is a frequent complication of type 2 diabetes (T2DM). Based on its multiple roles in inflammation, atherogenesis and glucose homeostasis, we hypothesised that activin A could be related to coronary atherosclerosis in T2DM. METHODS: Activin A and follistatin were measured in 102 patients with T2DM and 20 age- and sex-matched healthy controls. Coronary angiography was performed in a sub-population of patients and associations with activin A were examined using multiple linear regression. RESULTS: Serum activin A and the activin A/follistatin ratio were increased in patients with T2DM and coronary artery disease (CAD) compared with healthy volunteers and the elevated activin A was associated with the severity of coronary atherosclerotic burden as determined by the proportion of ≥2 vessel disease (p = 0.035) after multivariable-adjusted trend analysis. No significant association between presence of CAD or extent score and activin A was observed. CONCLUSION: In patients with T2DM, increased activin A may reflect chronic underlying pathophysiological processes involved in development of cardiovascular disease.
Authors: Jonathan W Lowery; Giuseppe Intini; Laura Gamer; Sutada Lotinun; Valerie S Salazar; Satoshi Ote; Karen Cox; Roland Baron; Vicki Rosen Journal: J Cell Sci Date: 2015-02-06 Impact factor: 5.285
Authors: Anders Nordholm; Søren Egstrand; Eva Gravesen; Maria L Mace; Marya Morevati; Klaus Olgaard; Ewa Lewin Journal: Pflugers Arch Date: 2019-06-24 Impact factor: 3.657
Authors: Weena J Y Chen; Sabrina Greulich; Rutger W van der Meer; Luuk J Rijzewijk; Hildo J Lamb; Albert de Roos; Johannes W A Smit; Johannes A Romijn; Johannes B Ruige; Adriaan A Lammertsma; Mark Lubberink; Michaela Diamant; D Margriet Ouwens Journal: Cardiovasc Diabetol Date: 2013-10-17 Impact factor: 9.951
Authors: Claus Brandt; Maria Pedersen; Anders Rinnov; Anne S Andreasen; Kirsten Møller; Pernille Hojman; Bente K Pedersen; Peter Plomgaard Journal: Mediators Inflamm Date: 2014-07-03 Impact factor: 4.711
Authors: Myong-Won Seo; Sung-Woo Jung; Sung-Woo Kim; Hyun Chul Jung; Deog-Yoon Kim; Jong Kook Song Journal: Int J Environ Res Public Health Date: 2020-09-10 Impact factor: 3.390